Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/breastcancer.1.005
Progress and perspectives of organoid cultures of primary human breast cancer
Nadine Goldhammer1,2, Ole William Petersen1,2,*
- 1Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark
- 2Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Denmark
Corresponding Author
Ole William Petersen, owp@sund.ku.dk
Received Date: March 24, 2021
Accepted Date: June 14, 2021
Goldhammer N, Peterson OW. Progress and perspectives of organoid cultures of primary human breast cancer. J Breast Cancer Res 2021; 1(1):17-19.
Copyright: © 2021 Goldhammer N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Organoid culture, Breast cancer, Microenvironment
Recommended Articles
Significance of BRCA genetic testing for preoperative breast cancer patients
Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation.
BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information
Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis. Review of literature may help characterize the distinctive differences between BRCA1 or BRCA2 breast tumors and subsequent metastasis to brain.
The role of MRI in detecting and characterizing brain metastases from breast cancer
Brain metastases are a feared complication of breast cancer, occurring in 15-25% of patients and being associated with poor prognosis and reduced quality of life. Magnetic resonance imaging (MRI) is an advanced technique that uses powerful magnetic fields and radio waves to produce detailed three-dimensional (3D) images of the brain's neuroanatomy and any potential pathology, especially in the management of brain metastases. The review article by Mohammadi et al. provides a timely and comprehensive overview of the utility of MRI for detecting and characterizing brain metastases from breast cancer.
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus. We have detected over 170 different RNA modifications, such as N6-methyladenosine (m6A), N7-methylguanosine (m7G), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N3-methylcytosine (m3C), and pseudouridine (ψ).These modifications are important for biological processes like RNA metabolism and post-transcriptional regulation.
Cryoablation is a safe alternative to surgery for low-risk breast cancer
Cryoablation of breast cancer offers an alternative to surgery for women who are not ideal surgical candidates. It is a minimally invasive procedure that has already had success in fibroadenoma treatment with good tumor reduction and cosmesis. The findings of cryoablation as treatment for early-stage, low-risk breast cancer has been previously discussed in the recently published article ‘Cryoablation: A promising non-operative therapy for low-risk breast cancer’.